Global Immuno-oncology Assay Market
Global Immuno-oncology Assay Market

Immuno-oncology Assay Comprehensive Study by Type (Consumables, Software), Application (Research & Development, Clinical Diagnostics), Technology (Immunoassay, Flow Cytometry, PCR, Next-Generation Sequencing, Other Technologies), Indication (Lung Cancer, Colorectal Cancer, Melanoma, Bladder Cancer, Other Cancers) Players and Region - Global Market Outlook to 2025

Immuno-oncology Assay Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Oct 2020 Edition 216 Pages 215 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Immuno-oncology Assay Market Scope?
Immuno-oncology refers to the use of the body's natural defenses to treat cancer and works by stimulating the immune system instead of fighting the tumors, avoiding disturbance in the functionality of healthy cells. The immuno-oncology assay is a type of immunoassay primarily used for cancer diagnosis. Further, ongoing clinical trials for the development of innovative products for cancer treatment is driving the immuno-oncology assay market.

The market study is being classified by Type (Consumables and Software), by Application (Research & Development and Clinical Diagnostics) and major geographies with country level break-up.

The Global Immuno-oncology Assay Market is fragmented with numerous market players. The key players in the market are focused on launching new products in the market, which is also expected to be another factor to drive market growth. Further, increasing incidence rate of cancer with various research and development activities, owing to benefits related to cancer treatment is propelling the market growth Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Immuno-oncology Assay market throughout the predicted period.

Thermo Fischer Scientific (United States), Roche Diagnostics (Switzerland), Agilent Technologies (United States), Illumina (United States), NanoString Technologies, Inc. (United States), Sartorius Group (Germany), Foundation Medicine, Inc. (United States), HTG Molecular Diagnostics, Inc. (United States), Qiagen (Germany), Merck & Co.(United States), PerkinElmer, Inc (United States), Nexelis (United States) and NeoGenomics Laboratories, Inc. (United States) are some of the key players profiled in the study.

Segmentation Analysis
AdvanceMarketAnalytics has segmented the market of Global Immuno-oncology Assay market by Type, Application and Region.

On the basis of geography, the market of Immuno-oncology Assay has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Market Influencers and their development strategies
In 2018, Roche collaborated with SQZ Biotech to develop antigen-presenting cells-based immune-oncology treatments.
In Mar 2020, Nexelis is pleased to announce the signing of a definitive agreement, subject to conditions precedent, to acquire ImmunXperts., and In Mar 2019, NeoGenomics, Inc. announced the availability of the Ventana PD-L1 (SP142) Assay for tumor tissue from patients with the triple-negative subtype of breast cancer.


Influencing Market Trend
  • Introduction of Multiplex Assays

Market Drivers
  • Increasing Incidence of Cancer and Increasing Adoption of Targeted Therapy
  • Growing Cases of Melanoma
  • Rise in Adoption of Personalized Medicines

Opportunities
  • Rising Focus on Biomarker Development
  • Increasing Demand for Better Healthcare Services in Developing Economies

Restraints
  • Unfavorable Regulatory and Reimbursement Scenario
  • High Cost of Immunotherapy Treatment

Challenges
  • High Attrition Rate in the Product Development Cycle
  • High Amount of Capital Investments and Low Benefit-Cost Ratio


Key Target Audience
Immuno-oncology Assay Manufacturers, Pharmaceutical Companies, Marketing and Consulting Firms, Industry Associations, Downstream Vendors, Potential Investors and Distributors/Traders/Suppliers

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research & Media features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.
Report Objectives / Segmentation Covered
By Type
  • Consumables
  • Software
By Application
  • Research & Development
  • Clinical Diagnostics
By Technology
  • Immunoassay
  • Flow Cytometry
  • PCR
  • Next-Generation Sequencing
  • Other Technologies

By Indication
  • Lung Cancer
  • Colorectal Cancer
  • Melanoma
  • Bladder Cancer
  • Other Cancers

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Incidence of Cancer and Increasing Adoption of Targeted Therapy
      • 3.2.2. Growing Cases of Melanoma
      • 3.2.3. Rise in Adoption of Personalized Medicines
    • 3.3. Market Challenges
      • 3.3.1. High Attrition Rate in the Product Development Cycle
      • 3.3.2. High Amount of Capital Investments and Low Benefit-Cost Ratio
    • 3.4. Market Trends
      • 3.4.1. Introduction of Multiplex Assays
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Immuno-oncology Assay, by Type, Application, Technology, Indication and Region (value) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Immuno-oncology Assay (Value)
      • 5.2.1. Global Immuno-oncology Assay by: Type (Value)
        • 5.2.1.1. Consumables
        • 5.2.1.2. Software
      • 5.2.2. Global Immuno-oncology Assay by: Application (Value)
        • 5.2.2.1. Research & Development
        • 5.2.2.2. Clinical Diagnostics
      • 5.2.3. Global Immuno-oncology Assay by: Technology (Value)
        • 5.2.3.1. Immunoassay
        • 5.2.3.2. Flow Cytometry
        • 5.2.3.3. PCR
        • 5.2.3.4. Next-Generation Sequencing
        • 5.2.3.5. Other Technologies
      • 5.2.4. Global Immuno-oncology Assay by: Indication (Value)
        • 5.2.4.1. Lung Cancer
        • 5.2.4.2. Colorectal Cancer
        • 5.2.4.3. Melanoma
        • 5.2.4.4. Bladder Cancer
        • 5.2.4.5. Other Cancers
      • 5.2.5. Global Immuno-oncology Assay Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Immuno-oncology Assay: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Thermo Fischer Scientific (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Roche Diagnostics (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Agilent Technologies (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Illumina (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. NanoString Technologies, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Sartorius Group (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Foundation Medicine, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. HTG Molecular Diagnostics, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Qiagen (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Merck & Co.(United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. PerkinElmer, Inc (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Nexelis (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. NeoGenomics Laboratories, Inc. (United States)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
  • 7. Global Immuno-oncology Assay Sale, by Type, Application, Technology, Indication and Region (value) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Immuno-oncology Assay (Value)
      • 7.2.1. Global Immuno-oncology Assay by: Type (Value)
        • 7.2.1.1. Consumables
        • 7.2.1.2. Software
      • 7.2.2. Global Immuno-oncology Assay by: Application (Value)
        • 7.2.2.1. Research & Development
        • 7.2.2.2. Clinical Diagnostics
      • 7.2.3. Global Immuno-oncology Assay by: Technology (Value)
        • 7.2.3.1. Immunoassay
        • 7.2.3.2. Flow Cytometry
        • 7.2.3.3. PCR
        • 7.2.3.4. Next-Generation Sequencing
        • 7.2.3.5. Other Technologies
      • 7.2.4. Global Immuno-oncology Assay by: Indication (Value)
        • 7.2.4.1. Lung Cancer
        • 7.2.4.2. Colorectal Cancer
        • 7.2.4.3. Melanoma
        • 7.2.4.4. Bladder Cancer
        • 7.2.4.5. Other Cancers
      • 7.2.5. Global Immuno-oncology Assay Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Immuno-oncology Assay: by Type(USD Million)
  • Table 2. Immuno-oncology Assay Consumables , by Region USD Million (2014-2019)
  • Table 3. Immuno-oncology Assay Software , by Region USD Million (2014-2019)
  • Table 4. Immuno-oncology Assay: by Application(USD Million)
  • Table 5. Immuno-oncology Assay Research & Development , by Region USD Million (2014-2019)
  • Table 6. Immuno-oncology Assay Clinical Diagnostics , by Region USD Million (2014-2019)
  • Table 7. Immuno-oncology Assay: by Technology(USD Million)
  • Table 8. Immuno-oncology Assay Immunoassay , by Region USD Million (2014-2019)
  • Table 9. Immuno-oncology Assay Flow Cytometry , by Region USD Million (2014-2019)
  • Table 10. Immuno-oncology Assay PCR , by Region USD Million (2014-2019)
  • Table 11. Immuno-oncology Assay Next-Generation Sequencing , by Region USD Million (2014-2019)
  • Table 12. Immuno-oncology Assay Other Technologies , by Region USD Million (2014-2019)
  • Table 13. Immuno-oncology Assay: by Indication(USD Million)
  • Table 14. Immuno-oncology Assay Lung Cancer , by Region USD Million (2014-2019)
  • Table 15. Immuno-oncology Assay Colorectal Cancer , by Region USD Million (2014-2019)
  • Table 16. Immuno-oncology Assay Melanoma , by Region USD Million (2014-2019)
  • Table 17. Immuno-oncology Assay Bladder Cancer , by Region USD Million (2014-2019)
  • Table 18. Immuno-oncology Assay Other Cancers , by Region USD Million (2014-2019)
  • Table 19. South America Immuno-oncology Assay, by Country USD Million (2014-2019)
  • Table 20. South America Immuno-oncology Assay, by Type USD Million (2014-2019)
  • Table 21. South America Immuno-oncology Assay, by Application USD Million (2014-2019)
  • Table 22. South America Immuno-oncology Assay, by Technology USD Million (2014-2019)
  • Table 23. South America Immuno-oncology Assay, by Indication USD Million (2014-2019)
  • Table 24. Brazil Immuno-oncology Assay, by Type USD Million (2014-2019)
  • Table 25. Brazil Immuno-oncology Assay, by Application USD Million (2014-2019)
  • Table 26. Brazil Immuno-oncology Assay, by Technology USD Million (2014-2019)
  • Table 27. Brazil Immuno-oncology Assay, by Indication USD Million (2014-2019)
  • Table 28. Argentina Immuno-oncology Assay, by Type USD Million (2014-2019)
  • Table 29. Argentina Immuno-oncology Assay, by Application USD Million (2014-2019)
  • Table 30. Argentina Immuno-oncology Assay, by Technology USD Million (2014-2019)
  • Table 31. Argentina Immuno-oncology Assay, by Indication USD Million (2014-2019)
  • Table 32. Rest of South America Immuno-oncology Assay, by Type USD Million (2014-2019)
  • Table 33. Rest of South America Immuno-oncology Assay, by Application USD Million (2014-2019)
  • Table 34. Rest of South America Immuno-oncology Assay, by Technology USD Million (2014-2019)
  • Table 35. Rest of South America Immuno-oncology Assay, by Indication USD Million (2014-2019)
  • Table 36. Asia Pacific Immuno-oncology Assay, by Country USD Million (2014-2019)
  • Table 37. Asia Pacific Immuno-oncology Assay, by Type USD Million (2014-2019)
  • Table 38. Asia Pacific Immuno-oncology Assay, by Application USD Million (2014-2019)
  • Table 39. Asia Pacific Immuno-oncology Assay, by Technology USD Million (2014-2019)
  • Table 40. Asia Pacific Immuno-oncology Assay, by Indication USD Million (2014-2019)
  • Table 41. China Immuno-oncology Assay, by Type USD Million (2014-2019)
  • Table 42. China Immuno-oncology Assay, by Application USD Million (2014-2019)
  • Table 43. China Immuno-oncology Assay, by Technology USD Million (2014-2019)
  • Table 44. China Immuno-oncology Assay, by Indication USD Million (2014-2019)
  • Table 45. Japan Immuno-oncology Assay, by Type USD Million (2014-2019)
  • Table 46. Japan Immuno-oncology Assay, by Application USD Million (2014-2019)
  • Table 47. Japan Immuno-oncology Assay, by Technology USD Million (2014-2019)
  • Table 48. Japan Immuno-oncology Assay, by Indication USD Million (2014-2019)
  • Table 49. India Immuno-oncology Assay, by Type USD Million (2014-2019)
  • Table 50. India Immuno-oncology Assay, by Application USD Million (2014-2019)
  • Table 51. India Immuno-oncology Assay, by Technology USD Million (2014-2019)
  • Table 52. India Immuno-oncology Assay, by Indication USD Million (2014-2019)
  • Table 53. South Korea Immuno-oncology Assay, by Type USD Million (2014-2019)
  • Table 54. South Korea Immuno-oncology Assay, by Application USD Million (2014-2019)
  • Table 55. South Korea Immuno-oncology Assay, by Technology USD Million (2014-2019)
  • Table 56. South Korea Immuno-oncology Assay, by Indication USD Million (2014-2019)
  • Table 57. Taiwan Immuno-oncology Assay, by Type USD Million (2014-2019)
  • Table 58. Taiwan Immuno-oncology Assay, by Application USD Million (2014-2019)
  • Table 59. Taiwan Immuno-oncology Assay, by Technology USD Million (2014-2019)
  • Table 60. Taiwan Immuno-oncology Assay, by Indication USD Million (2014-2019)
  • Table 61. Australia Immuno-oncology Assay, by Type USD Million (2014-2019)
  • Table 62. Australia Immuno-oncology Assay, by Application USD Million (2014-2019)
  • Table 63. Australia Immuno-oncology Assay, by Technology USD Million (2014-2019)
  • Table 64. Australia Immuno-oncology Assay, by Indication USD Million (2014-2019)
  • Table 65. Rest of Asia-Pacific Immuno-oncology Assay, by Type USD Million (2014-2019)
  • Table 66. Rest of Asia-Pacific Immuno-oncology Assay, by Application USD Million (2014-2019)
  • Table 67. Rest of Asia-Pacific Immuno-oncology Assay, by Technology USD Million (2014-2019)
  • Table 68. Rest of Asia-Pacific Immuno-oncology Assay, by Indication USD Million (2014-2019)
  • Table 69. Europe Immuno-oncology Assay, by Country USD Million (2014-2019)
  • Table 70. Europe Immuno-oncology Assay, by Type USD Million (2014-2019)
  • Table 71. Europe Immuno-oncology Assay, by Application USD Million (2014-2019)
  • Table 72. Europe Immuno-oncology Assay, by Technology USD Million (2014-2019)
  • Table 73. Europe Immuno-oncology Assay, by Indication USD Million (2014-2019)
  • Table 74. Germany Immuno-oncology Assay, by Type USD Million (2014-2019)
  • Table 75. Germany Immuno-oncology Assay, by Application USD Million (2014-2019)
  • Table 76. Germany Immuno-oncology Assay, by Technology USD Million (2014-2019)
  • Table 77. Germany Immuno-oncology Assay, by Indication USD Million (2014-2019)
  • Table 78. France Immuno-oncology Assay, by Type USD Million (2014-2019)
  • Table 79. France Immuno-oncology Assay, by Application USD Million (2014-2019)
  • Table 80. France Immuno-oncology Assay, by Technology USD Million (2014-2019)
  • Table 81. France Immuno-oncology Assay, by Indication USD Million (2014-2019)
  • Table 82. Italy Immuno-oncology Assay, by Type USD Million (2014-2019)
  • Table 83. Italy Immuno-oncology Assay, by Application USD Million (2014-2019)
  • Table 84. Italy Immuno-oncology Assay, by Technology USD Million (2014-2019)
  • Table 85. Italy Immuno-oncology Assay, by Indication USD Million (2014-2019)
  • Table 86. United Kingdom Immuno-oncology Assay, by Type USD Million (2014-2019)
  • Table 87. United Kingdom Immuno-oncology Assay, by Application USD Million (2014-2019)
  • Table 88. United Kingdom Immuno-oncology Assay, by Technology USD Million (2014-2019)
  • Table 89. United Kingdom Immuno-oncology Assay, by Indication USD Million (2014-2019)
  • Table 90. Netherlands Immuno-oncology Assay, by Type USD Million (2014-2019)
  • Table 91. Netherlands Immuno-oncology Assay, by Application USD Million (2014-2019)
  • Table 92. Netherlands Immuno-oncology Assay, by Technology USD Million (2014-2019)
  • Table 93. Netherlands Immuno-oncology Assay, by Indication USD Million (2014-2019)
  • Table 94. Rest of Europe Immuno-oncology Assay, by Type USD Million (2014-2019)
  • Table 95. Rest of Europe Immuno-oncology Assay, by Application USD Million (2014-2019)
  • Table 96. Rest of Europe Immuno-oncology Assay, by Technology USD Million (2014-2019)
  • Table 97. Rest of Europe Immuno-oncology Assay, by Indication USD Million (2014-2019)
  • Table 98. MEA Immuno-oncology Assay, by Country USD Million (2014-2019)
  • Table 99. MEA Immuno-oncology Assay, by Type USD Million (2014-2019)
  • Table 100. MEA Immuno-oncology Assay, by Application USD Million (2014-2019)
  • Table 101. MEA Immuno-oncology Assay, by Technology USD Million (2014-2019)
  • Table 102. MEA Immuno-oncology Assay, by Indication USD Million (2014-2019)
  • Table 103. Middle East Immuno-oncology Assay, by Type USD Million (2014-2019)
  • Table 104. Middle East Immuno-oncology Assay, by Application USD Million (2014-2019)
  • Table 105. Middle East Immuno-oncology Assay, by Technology USD Million (2014-2019)
  • Table 106. Middle East Immuno-oncology Assay, by Indication USD Million (2014-2019)
  • Table 107. Africa Immuno-oncology Assay, by Type USD Million (2014-2019)
  • Table 108. Africa Immuno-oncology Assay, by Application USD Million (2014-2019)
  • Table 109. Africa Immuno-oncology Assay, by Technology USD Million (2014-2019)
  • Table 110. Africa Immuno-oncology Assay, by Indication USD Million (2014-2019)
  • Table 111. North America Immuno-oncology Assay, by Country USD Million (2014-2019)
  • Table 112. North America Immuno-oncology Assay, by Type USD Million (2014-2019)
  • Table 113. North America Immuno-oncology Assay, by Application USD Million (2014-2019)
  • Table 114. North America Immuno-oncology Assay, by Technology USD Million (2014-2019)
  • Table 115. North America Immuno-oncology Assay, by Indication USD Million (2014-2019)
  • Table 116. United States Immuno-oncology Assay, by Type USD Million (2014-2019)
  • Table 117. United States Immuno-oncology Assay, by Application USD Million (2014-2019)
  • Table 118. United States Immuno-oncology Assay, by Technology USD Million (2014-2019)
  • Table 119. United States Immuno-oncology Assay, by Indication USD Million (2014-2019)
  • Table 120. Canada Immuno-oncology Assay, by Type USD Million (2014-2019)
  • Table 121. Canada Immuno-oncology Assay, by Application USD Million (2014-2019)
  • Table 122. Canada Immuno-oncology Assay, by Technology USD Million (2014-2019)
  • Table 123. Canada Immuno-oncology Assay, by Indication USD Million (2014-2019)
  • Table 124. Mexico Immuno-oncology Assay, by Type USD Million (2014-2019)
  • Table 125. Mexico Immuno-oncology Assay, by Application USD Million (2014-2019)
  • Table 126. Mexico Immuno-oncology Assay, by Technology USD Million (2014-2019)
  • Table 127. Mexico Immuno-oncology Assay, by Indication USD Million (2014-2019)
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Immuno-oncology Assay: by Type(USD Million)
  • Table 142. Immuno-oncology Assay Consumables , by Region USD Million (2020-2025)
  • Table 143. Immuno-oncology Assay Software , by Region USD Million (2020-2025)
  • Table 144. Immuno-oncology Assay: by Application(USD Million)
  • Table 145. Immuno-oncology Assay Research & Development , by Region USD Million (2020-2025)
  • Table 146. Immuno-oncology Assay Clinical Diagnostics , by Region USD Million (2020-2025)
  • Table 147. Immuno-oncology Assay: by Technology(USD Million)
  • Table 148. Immuno-oncology Assay Immunoassay , by Region USD Million (2020-2025)
  • Table 149. Immuno-oncology Assay Flow Cytometry , by Region USD Million (2020-2025)
  • Table 150. Immuno-oncology Assay PCR , by Region USD Million (2020-2025)
  • Table 151. Immuno-oncology Assay Next-Generation Sequencing , by Region USD Million (2020-2025)
  • Table 152. Immuno-oncology Assay Other Technologies , by Region USD Million (2020-2025)
  • Table 153. Immuno-oncology Assay: by Indication(USD Million)
  • Table 154. Immuno-oncology Assay Lung Cancer , by Region USD Million (2020-2025)
  • Table 155. Immuno-oncology Assay Colorectal Cancer , by Region USD Million (2020-2025)
  • Table 156. Immuno-oncology Assay Melanoma , by Region USD Million (2020-2025)
  • Table 157. Immuno-oncology Assay Bladder Cancer , by Region USD Million (2020-2025)
  • Table 158. Immuno-oncology Assay Other Cancers , by Region USD Million (2020-2025)
  • Table 159. South America Immuno-oncology Assay, by Country USD Million (2020-2025)
  • Table 160. South America Immuno-oncology Assay, by Type USD Million (2020-2025)
  • Table 161. South America Immuno-oncology Assay, by Application USD Million (2020-2025)
  • Table 162. South America Immuno-oncology Assay, by Technology USD Million (2020-2025)
  • Table 163. South America Immuno-oncology Assay, by Indication USD Million (2020-2025)
  • Table 164. Brazil Immuno-oncology Assay, by Type USD Million (2020-2025)
  • Table 165. Brazil Immuno-oncology Assay, by Application USD Million (2020-2025)
  • Table 166. Brazil Immuno-oncology Assay, by Technology USD Million (2020-2025)
  • Table 167. Brazil Immuno-oncology Assay, by Indication USD Million (2020-2025)
  • Table 168. Argentina Immuno-oncology Assay, by Type USD Million (2020-2025)
  • Table 169. Argentina Immuno-oncology Assay, by Application USD Million (2020-2025)
  • Table 170. Argentina Immuno-oncology Assay, by Technology USD Million (2020-2025)
  • Table 171. Argentina Immuno-oncology Assay, by Indication USD Million (2020-2025)
  • Table 172. Rest of South America Immuno-oncology Assay, by Type USD Million (2020-2025)
  • Table 173. Rest of South America Immuno-oncology Assay, by Application USD Million (2020-2025)
  • Table 174. Rest of South America Immuno-oncology Assay, by Technology USD Million (2020-2025)
  • Table 175. Rest of South America Immuno-oncology Assay, by Indication USD Million (2020-2025)
  • Table 176. Asia Pacific Immuno-oncology Assay, by Country USD Million (2020-2025)
  • Table 177. Asia Pacific Immuno-oncology Assay, by Type USD Million (2020-2025)
  • Table 178. Asia Pacific Immuno-oncology Assay, by Application USD Million (2020-2025)
  • Table 179. Asia Pacific Immuno-oncology Assay, by Technology USD Million (2020-2025)
  • Table 180. Asia Pacific Immuno-oncology Assay, by Indication USD Million (2020-2025)
  • Table 181. China Immuno-oncology Assay, by Type USD Million (2020-2025)
  • Table 182. China Immuno-oncology Assay, by Application USD Million (2020-2025)
  • Table 183. China Immuno-oncology Assay, by Technology USD Million (2020-2025)
  • Table 184. China Immuno-oncology Assay, by Indication USD Million (2020-2025)
  • Table 185. Japan Immuno-oncology Assay, by Type USD Million (2020-2025)
  • Table 186. Japan Immuno-oncology Assay, by Application USD Million (2020-2025)
  • Table 187. Japan Immuno-oncology Assay, by Technology USD Million (2020-2025)
  • Table 188. Japan Immuno-oncology Assay, by Indication USD Million (2020-2025)
  • Table 189. India Immuno-oncology Assay, by Type USD Million (2020-2025)
  • Table 190. India Immuno-oncology Assay, by Application USD Million (2020-2025)
  • Table 191. India Immuno-oncology Assay, by Technology USD Million (2020-2025)
  • Table 192. India Immuno-oncology Assay, by Indication USD Million (2020-2025)
  • Table 193. South Korea Immuno-oncology Assay, by Type USD Million (2020-2025)
  • Table 194. South Korea Immuno-oncology Assay, by Application USD Million (2020-2025)
  • Table 195. South Korea Immuno-oncology Assay, by Technology USD Million (2020-2025)
  • Table 196. South Korea Immuno-oncology Assay, by Indication USD Million (2020-2025)
  • Table 197. Taiwan Immuno-oncology Assay, by Type USD Million (2020-2025)
  • Table 198. Taiwan Immuno-oncology Assay, by Application USD Million (2020-2025)
  • Table 199. Taiwan Immuno-oncology Assay, by Technology USD Million (2020-2025)
  • Table 200. Taiwan Immuno-oncology Assay, by Indication USD Million (2020-2025)
  • Table 201. Australia Immuno-oncology Assay, by Type USD Million (2020-2025)
  • Table 202. Australia Immuno-oncology Assay, by Application USD Million (2020-2025)
  • Table 203. Australia Immuno-oncology Assay, by Technology USD Million (2020-2025)
  • Table 204. Australia Immuno-oncology Assay, by Indication USD Million (2020-2025)
  • Table 205. Rest of Asia-Pacific Immuno-oncology Assay, by Type USD Million (2020-2025)
  • Table 206. Rest of Asia-Pacific Immuno-oncology Assay, by Application USD Million (2020-2025)
  • Table 207. Rest of Asia-Pacific Immuno-oncology Assay, by Technology USD Million (2020-2025)
  • Table 208. Rest of Asia-Pacific Immuno-oncology Assay, by Indication USD Million (2020-2025)
  • Table 209. Europe Immuno-oncology Assay, by Country USD Million (2020-2025)
  • Table 210. Europe Immuno-oncology Assay, by Type USD Million (2020-2025)
  • Table 211. Europe Immuno-oncology Assay, by Application USD Million (2020-2025)
  • Table 212. Europe Immuno-oncology Assay, by Technology USD Million (2020-2025)
  • Table 213. Europe Immuno-oncology Assay, by Indication USD Million (2020-2025)
  • Table 214. Germany Immuno-oncology Assay, by Type USD Million (2020-2025)
  • Table 215. Germany Immuno-oncology Assay, by Application USD Million (2020-2025)
  • Table 216. Germany Immuno-oncology Assay, by Technology USD Million (2020-2025)
  • Table 217. Germany Immuno-oncology Assay, by Indication USD Million (2020-2025)
  • Table 218. France Immuno-oncology Assay, by Type USD Million (2020-2025)
  • Table 219. France Immuno-oncology Assay, by Application USD Million (2020-2025)
  • Table 220. France Immuno-oncology Assay, by Technology USD Million (2020-2025)
  • Table 221. France Immuno-oncology Assay, by Indication USD Million (2020-2025)
  • Table 222. Italy Immuno-oncology Assay, by Type USD Million (2020-2025)
  • Table 223. Italy Immuno-oncology Assay, by Application USD Million (2020-2025)
  • Table 224. Italy Immuno-oncology Assay, by Technology USD Million (2020-2025)
  • Table 225. Italy Immuno-oncology Assay, by Indication USD Million (2020-2025)
  • Table 226. United Kingdom Immuno-oncology Assay, by Type USD Million (2020-2025)
  • Table 227. United Kingdom Immuno-oncology Assay, by Application USD Million (2020-2025)
  • Table 228. United Kingdom Immuno-oncology Assay, by Technology USD Million (2020-2025)
  • Table 229. United Kingdom Immuno-oncology Assay, by Indication USD Million (2020-2025)
  • Table 230. Netherlands Immuno-oncology Assay, by Type USD Million (2020-2025)
  • Table 231. Netherlands Immuno-oncology Assay, by Application USD Million (2020-2025)
  • Table 232. Netherlands Immuno-oncology Assay, by Technology USD Million (2020-2025)
  • Table 233. Netherlands Immuno-oncology Assay, by Indication USD Million (2020-2025)
  • Table 234. Rest of Europe Immuno-oncology Assay, by Type USD Million (2020-2025)
  • Table 235. Rest of Europe Immuno-oncology Assay, by Application USD Million (2020-2025)
  • Table 236. Rest of Europe Immuno-oncology Assay, by Technology USD Million (2020-2025)
  • Table 237. Rest of Europe Immuno-oncology Assay, by Indication USD Million (2020-2025)
  • Table 238. MEA Immuno-oncology Assay, by Country USD Million (2020-2025)
  • Table 239. MEA Immuno-oncology Assay, by Type USD Million (2020-2025)
  • Table 240. MEA Immuno-oncology Assay, by Application USD Million (2020-2025)
  • Table 241. MEA Immuno-oncology Assay, by Technology USD Million (2020-2025)
  • Table 242. MEA Immuno-oncology Assay, by Indication USD Million (2020-2025)
  • Table 243. Middle East Immuno-oncology Assay, by Type USD Million (2020-2025)
  • Table 244. Middle East Immuno-oncology Assay, by Application USD Million (2020-2025)
  • Table 245. Middle East Immuno-oncology Assay, by Technology USD Million (2020-2025)
  • Table 246. Middle East Immuno-oncology Assay, by Indication USD Million (2020-2025)
  • Table 247. Africa Immuno-oncology Assay, by Type USD Million (2020-2025)
  • Table 248. Africa Immuno-oncology Assay, by Application USD Million (2020-2025)
  • Table 249. Africa Immuno-oncology Assay, by Technology USD Million (2020-2025)
  • Table 250. Africa Immuno-oncology Assay, by Indication USD Million (2020-2025)
  • Table 251. North America Immuno-oncology Assay, by Country USD Million (2020-2025)
  • Table 252. North America Immuno-oncology Assay, by Type USD Million (2020-2025)
  • Table 253. North America Immuno-oncology Assay, by Application USD Million (2020-2025)
  • Table 254. North America Immuno-oncology Assay, by Technology USD Million (2020-2025)
  • Table 255. North America Immuno-oncology Assay, by Indication USD Million (2020-2025)
  • Table 256. United States Immuno-oncology Assay, by Type USD Million (2020-2025)
  • Table 257. United States Immuno-oncology Assay, by Application USD Million (2020-2025)
  • Table 258. United States Immuno-oncology Assay, by Technology USD Million (2020-2025)
  • Table 259. United States Immuno-oncology Assay, by Indication USD Million (2020-2025)
  • Table 260. Canada Immuno-oncology Assay, by Type USD Million (2020-2025)
  • Table 261. Canada Immuno-oncology Assay, by Application USD Million (2020-2025)
  • Table 262. Canada Immuno-oncology Assay, by Technology USD Million (2020-2025)
  • Table 263. Canada Immuno-oncology Assay, by Indication USD Million (2020-2025)
  • Table 264. Mexico Immuno-oncology Assay, by Type USD Million (2020-2025)
  • Table 265. Mexico Immuno-oncology Assay, by Application USD Million (2020-2025)
  • Table 266. Mexico Immuno-oncology Assay, by Technology USD Million (2020-2025)
  • Table 267. Mexico Immuno-oncology Assay, by Indication USD Million (2020-2025)
  • Table 268. Research Programs/Design for This Report
  • Table 269. Key Data Information from Secondary Sources
  • Table 270. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Immuno-oncology Assay: by Type USD Million (2014-2019)
  • Figure 5. Global Immuno-oncology Assay: by Application USD Million (2014-2019)
  • Figure 6. Global Immuno-oncology Assay: by Technology USD Million (2014-2019)
  • Figure 7. Global Immuno-oncology Assay: by Indication USD Million (2014-2019)
  • Figure 8. South America Immuno-oncology Assay Share (%), by Country
  • Figure 9. Asia Pacific Immuno-oncology Assay Share (%), by Country
  • Figure 10. Europe Immuno-oncology Assay Share (%), by Country
  • Figure 11. MEA Immuno-oncology Assay Share (%), by Country
  • Figure 12. North America Immuno-oncology Assay Share (%), by Country
  • Figure 13. Global Immuno-oncology Assay share by Players 2019 (%)
  • Figure 14. Global Immuno-oncology Assay share by Players (Top 3) 2019(%)
  • Figure 15. Global Immuno-oncology Assay share by Players (Top 5) 2019(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Thermo Fischer Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 18. Thermo Fischer Scientific (United States) Revenue: by Geography 2019
  • Figure 19. Roche Diagnostics (Switzerland) Revenue, Net Income and Gross profit
  • Figure 20. Roche Diagnostics (Switzerland) Revenue: by Geography 2019
  • Figure 21. Agilent Technologies (United States) Revenue, Net Income and Gross profit
  • Figure 22. Agilent Technologies (United States) Revenue: by Geography 2019
  • Figure 23. Illumina (United States) Revenue, Net Income and Gross profit
  • Figure 24. Illumina (United States) Revenue: by Geography 2019
  • Figure 25. NanoString Technologies, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. NanoString Technologies, Inc. (United States) Revenue: by Geography 2019
  • Figure 27. Sartorius Group (Germany) Revenue, Net Income and Gross profit
  • Figure 28. Sartorius Group (Germany) Revenue: by Geography 2019
  • Figure 29. Foundation Medicine, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Foundation Medicine, Inc. (United States) Revenue: by Geography 2019
  • Figure 31. HTG Molecular Diagnostics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. HTG Molecular Diagnostics, Inc. (United States) Revenue: by Geography 2019
  • Figure 33. Qiagen (Germany) Revenue, Net Income and Gross profit
  • Figure 34. Qiagen (Germany) Revenue: by Geography 2019
  • Figure 35. Merck & Co.(United States) Revenue, Net Income and Gross profit
  • Figure 36. Merck & Co.(United States) Revenue: by Geography 2019
  • Figure 37. PerkinElmer, Inc (United States) Revenue, Net Income and Gross profit
  • Figure 38. PerkinElmer, Inc (United States) Revenue: by Geography 2019
  • Figure 39. Nexelis (United States) Revenue, Net Income and Gross profit
  • Figure 40. Nexelis (United States) Revenue: by Geography 2019
  • Figure 41. NeoGenomics Laboratories, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 42. NeoGenomics Laboratories, Inc. (United States) Revenue: by Geography 2019
  • Figure 43. Global Immuno-oncology Assay: by Type USD Million (2020-2025)
  • Figure 44. Global Immuno-oncology Assay: by Application USD Million (2020-2025)
  • Figure 45. Global Immuno-oncology Assay: by Technology USD Million (2020-2025)
  • Figure 46. Global Immuno-oncology Assay: by Indication USD Million (2020-2025)
  • Figure 47. South America Immuno-oncology Assay Share (%), by Country
  • Figure 48. Asia Pacific Immuno-oncology Assay Share (%), by Country
  • Figure 49. Europe Immuno-oncology Assay Share (%), by Country
  • Figure 50. MEA Immuno-oncology Assay Share (%), by Country
  • Figure 51. North America Immuno-oncology Assay Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Thermo Fischer Scientific (United States)
  • Roche Diagnostics (Switzerland)
  • Agilent Technologies (United States)
  • Illumina (United States)
  • NanoString Technologies, Inc. (United States)
  • Sartorius Group (Germany)
  • Foundation Medicine, Inc. (United States)
  • HTG Molecular Diagnostics, Inc. (United States)
  • Qiagen (Germany)
  • Merck & Co.(United States)
  • PerkinElmer, Inc (United States)
  • Nexelis (United States)
  • NeoGenomics Laboratories, Inc. (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation